11 August 2022 - - US-based PCR-based DNA technologies developer Applied DNA Sciences, Inc's (NASDAQ: APDN) LineaRx majority-owned biotherapeutics subsidiary has for the first time successfully administered and expressed a linearDNA-LNP construct in mice via routine intramuscular injection without the concurrent use of electroporation that utilizes electrical pulses to deliver DNA to target cells, the company said.

The company said it believes that the removal of the concurrent use of EP during administration potentially increases the commercial viability of LinearDNA-based therapies.

IM administered mRNA vaccines delivered via LNPs have altered the course of the COVID-19 pandemic.

Using similar LNP technology, LineaRx has achieved expression in mice of a linearDNA-LNP construct encoding reporter proteins via simple IM injection.

Unlike previous LinearDNA animal studies, concurrent EP was not utilized. The linearDNA-LNP construct used in the successful study was developed and manufactured by Applied DNA.

Based on LineaRx's previous successes in the expression of various DNA constructs, including its therapeutic anti-lymphoma vaccine, CD123, and its epitope-optimized Spike gene from SARS-CoV-2, the company believes that linearDNA-LNP constructs hold the potential to be used across a wide variety of therapeutic applications.

Near term, LineaRx is working to formulate its canine lymphoma vaccine candidate for IM administration via LNP.

LineaRx, an Applied DNA Sciences, Inc. (NASDAQ: APDN) company, was formed in 2018 to commercialize the parent company's 20+ years of experience in polymerase chain reaction -based DNA manufacturing and leadership in enzymatic DNA production.

LineaRx is developing and commercializing the LinearDNA platform as a cell-free enzymatic platform for the large-scale DNA manufacture of high-fidelity DNA sequences for use in nucleic acid-based therapeutics.

DNA manufactured via the platform is free of adventitious DNA sequences and can be chemically modified to optimize DNA for specific applications, offering compelling advantages over plasmid DNA in many biotherapeutic applications, from mRNA and DNA vaccines to redirected cell and gene therapies.

Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid.